Histone deacetylase inhibitors--a new tool to treat cancer

Cancer Treatment Reviews
Raz SomechAmos J Simon

Abstract

Transcriptional regulation in eukaryotes is a multilevel hierarchical process. It is becoming clear that higher-order chromatin structure, occurring via modifications of histones in their nucleosome structure, plays a crucial role in regulating gene expression, both in normal and pathological states. Deacetylation of histones by histone deacetylases (HDACs) modifies the chromatin from an open gene active euchromatin structure to a closed gene silenced heterochromatin structure. Several cancer promoting mutations and chromosomal translocations result in repression of transcription through abnormal recruitment and activation of HDACs, leading to neoplastic transformation. This is the rationale for the evolvement of HDAC inhibitors as a new class in cancer therapy. Trials have shown anti-proliferation effect of histone deacetylase inhibitors in cell culture, animal models and in human with both hematological and solid tumors. The exact mechanism by which histone deacetylase inhibitors exert their effect is still obscure. Reversal of the alteration in gene expression by fusion transcription factors or overexpressed repressors is just one of several possible explanations. The territory of heterochromatin in the vicinity of the nucle...Continue Reading

References

Jul 3, 1995·Proceedings of the National Academy of Sciences of the United States of America·J E Brownell, C D Allis
Sep 2, 1998·Journal of Structural Biology·N StuurmanU Aebi
Nov 12, 1998·Journal of the National Cancer Institute·R P WarrellP P Pandolfi
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·A SaitoO Nakanishi
Mar 4, 2000·Nature Genetics·S A GaytherC Caldas
May 12, 2000·Journal of Structural Biology·Y GruenbaumM Cohen
Jun 13, 2000·The Journal of Cell Biology·R D MoirR D Goldman
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Oct 12, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L J Burke, A Baniahmad
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·B E BernsteinS L Schreiber
Dec 7, 2000·Molecular Cell·T I GerasimovaV G Corces
Dec 7, 2000·Medical and Pediatric Oncology·D C CoffeyM P LaQuaglia
Apr 3, 2001·Frontiers in Bioscience : a Journal and Virtual Library·C WangR G Pestell
Apr 9, 2001·Investigational New Drugs·S PrakashP M LoRusso
Jul 27, 2001·Nucleic Acids Research·E NicolasD Trouche
Aug 11, 2001·Science·T Jenuwein, C D Allis
Oct 24, 2001·Current Opinion in Oncology·P A MarksR A Rifkind
Feb 21, 2002·The Journal of Cell Biology·Timothy P SpannRobert D Goldman
Mar 6, 2002·Genes & Development·Robert D GoldmanTimothy P Spann
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Mar 29, 2002·The Journal of Biological Chemistry·Scott C GalasinskiNatalie G Ahn
Jun 14, 2002·Seminars in Oncology·Minetta C Liu, Edward P Gelmann
Jun 18, 2002·Current Opinion in Cell Biology·Monika Lachner, Thomas Jenuwein
Jun 18, 2002·Current Opinion in Cell Biology·James M HolaskaMalini Mansharamani
Jun 19, 2002·Journal of Medical Genetics·I CoupryB Arveiler

❮ Previous
Next ❯

Citations

Mar 14, 2007·Apoptosis : an International Journal on Programmed Cell Death·S EmanueleG Tesoriere
Aug 10, 2007·Neuroscience Bulletin·Hai-Liang Tang, Jian-Hong Zhu
Nov 30, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xia ZhaoGuosheng Jiang
Jun 21, 2005·The International Journal of Biochemistry & Cell Biology·Lucia AltucciHinrich Gronemeyer
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Jun 1, 2005·European Journal of Medicinal Chemistry·Patrick AngibaudMichel Janicot
Oct 5, 2007·Transactions of the Royal Society of Tropical Medicine and Hygiene·John A Phillips, Beverly E Griffin
Jul 23, 2008·Journal of the American Chemical Society·Albert BowersRobert M Williams
Jul 31, 2010·Journal of Medicinal Chemistry·Sandra C MwakwariAdegboyega K Oyelere
Jan 22, 2008·Organic Letters·Thomas J GreshockRobert M Williams
Jul 13, 2006·Journal of Occupational Health Psychology·Ginger C HansonCari L Colton
Jan 28, 2006·Nucleosides, Nucleotides & Nucleic Acids·Jennifer Sigmond, Godfridus J Peters
Mar 14, 2007·Anti-cancer Drugs·Claude Monneret
Apr 22, 2005·Clinical Chemistry and Laboratory Medicine : CCLM·João GonçalvesMiguel Brito
Jun 20, 2014·ACS Medicinal Chemistry Letters·Fei ChenFa-Jun Nan
Apr 18, 2013·Molecular BioSystems·Jade M BeauharnoisJohn T Welch
Jun 28, 2007·Expert Opinion on Investigational Drugs·Madeleine Duvic, Jenny Vu
Mar 13, 2010·Cancer Treatment Reviews·Jean Pierre Bourquin, Shai Izraeli
Sep 28, 2007·Bioorganic & Medicinal Chemistry Letters·Cédric CharrierPhilippe Bertrand
May 17, 2005·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Jochen A StadlerCarl J Neumann
Nov 19, 2005·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Tania M Schroeder, Jennifer J Westendorf
May 10, 2007·The FEBS Journal·Sigal ShaklaiAmos J Simon
Jan 19, 2007·International Journal of Cancer. Journal International Du Cancer·Sarah E FurchertMichael C Frühwald
Nov 16, 2010·Angewandte Chemie·Alex M Szpilman, Erick M Carreira
Feb 20, 2016·Expert Review of Molecular Diagnostics·Louise WalshTríona Ní Chonghaile
Jan 31, 2014·Chemistry : a European Journal·Christoph SchotesBernhard Breit
Mar 15, 2005·Journal of Hepatology·Norifumi HarimotoYoshihiko Maehara
Jan 12, 2005·European Journal of Medicinal Chemistry·Claude Monneret
Aug 15, 2006·Bioorganic & Medicinal Chemistry Letters·Cédric CharrierJoëlle Roche
Apr 12, 2005·European Journal of Cell Biology·Tim C Roloff, Ulrike A Nuber
Dec 4, 2013·Bioorganic & Medicinal Chemistry·Qiu TanLi Zhu
May 15, 2015·Bioorganic Chemistry·Hendra Wahyudi, Shelli R McAlpine
Nov 9, 2010·European Journal of Medicinal Chemistry·Agostino MarrazzoGiuseppe Ronsisvalle
Sep 16, 2014·Neoplasia : an International Journal for Oncology Research·Tao ZhangZhengfang Yi
Mar 30, 2013·Biochemical and Biophysical Research Communications·Seiko FujiiTatsuji Nishihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis